Introduction: Although chronological age was key factor for frailty, it is not directly predicting biological age. We aimed to investigate biological age using quantitative frailty assessment tool: frailty discriminant score (FDS) and evaluated the relationship between the biological age and prognosis inpatients with urological cancers.
Methods: This study included 2819 control individuals and 863 urological cancer patients who evaluated frailty using FDS between April 2013 and May 2019. A formula of biological age was retrospectively estimated using the non-linear regression curve between the FDS and chronological age in control individuals and the gap between the chronological and biological age was calculated using the formula. The association between the biological age and overall survival was evaluated using Kaplan-Meier curve and Cox regression analysis.
Results: Median age of control and urological cancer groups was 55 and 71 years, respectively. The urological cancers included urothelial carcinoma (n=361), renal cell carcinoma (n=141), and prostate cancer (n=361). The formula for biological age in the control group was: Age = -0.4376*FDS^2 + 11.796*FDS + 58.79 (R^2 = 0.2847). The gap between the chronological and biological age was 13.4, 14.2, and 10.9 years in urothelial carcinoma, renal cell carcinoma, and prostate cancer, respectively. The age gap >30 years showed significantly poor overall survival.
Conclusions: Frailty might indicate biological age in urological cancer patients and it has potential to predict prognosis. Source of